Se Hoon Park

20PUBLICATIONS
117CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 06, 2026
Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis.

|Apr 09, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Jose Luis Perez-Gracia, Begoña Mellado, Aaron Richard Hansen

|Jan 28, 2026
Effect of First-Line Combination Systemic Therapy on Favorable-Risk Clear Cell Renal Cell Carcinoma: A Retrospective Study.

Soon Il Lee, Minsuk Kwon, Sung Hee Lim

|Nov 04, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study).

Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon

|Oct 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Francesco Massari, Matteo Rosellini, Bohuslav Melichar

|Jul 08, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

Mimma Rizzo, Andrey Soares, Shilpa Gupta

Pageof 4

Frequent Collaborators

3 joint publications

Javier Molina-Cerrillo

3 joint publications

Sebastiano Buti

2 joint publications

Youjin Kim

2 joint publications

Su Jin Lee